Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Cost-Effectiveness of Strategies to Personalize the Selection of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome.

Kim K, Touchette DR, Cavallari LH, Ardati AK, DiDomenico RJ.

Cardiovasc Drugs Ther. 2019 Jul 31. doi: 10.1007/s10557-019-06896-8. [Epub ahead of print]

PMID:
31367811
2.

Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome.

Kim K, Lee TA, Touchette DR, DiDomenico RJ, Ardati AK, Walton SM.

J Manag Care Spec Pharm. 2018 Aug;24(8):800-812. doi: 10.18553/jmcp.2018.24.8.800.

3.

Transradial Percutaneous Coronary Intervention... Works Great! Less Billing!

Ardati AK, Cohen DJ.

Circ Cardiovasc Qual Outcomes. 2018 May;11(5):e004667. doi: 10.1161/CIRCOUTCOMES.118.004667. No abstract available.

PMID:
29743164
4.

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

Cavallari LH, Lee CR, Beitelshees AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, Clare-Salzler MJ, Coons JC, Denny JC, Dillon C, Elsey AR, Hamadeh IS, Harada S, Hillegass WB, Hines L, Horenstein RB, Howell LA, Jeng LJB, Kelemen MD, Lee YM, Magvanjav O, Montasser M, Nelson DR, Nutescu EA, Nwaba DC, Pakyz RE, Palmer K, Peterson JF, Pollin TI, Quinn AH, Robinson SW, Schub J, Skaar TC, Smith DM, Sriramoju VB, Starostik P, Stys TP, Stevenson JM, Varunok N, Vesely MR, Wake DT, Weck KE, Weitzel KW, Wilke RA, Willig J, Zhao RY, Kreutz RP, Stouffer GA, Empey PE, Limdi NA, Shuldiner AR, Winterstein AG, Johnson JA; IGNITE Network.

JACC Cardiovasc Interv. 2018 Jan 22;11(2):181-191. doi: 10.1016/j.jcin.2017.07.022. Epub 2017 Nov 1.

5.

Comparative Effectiveness of Oral Antiplatelet Agents in Patients with Acute Coronary Syndrome.

Kim K, Lee TA, Ardati AK, DiDomenico RJ, Touchette DR, Walton SM.

Pharmacotherapy. 2017 Aug;37(8):877-887. doi: 10.1002/phar.1961. Epub 2017 Jul 18.

PMID:
28555946
6.

Effects of staged versus ad hoc percutaneous coronary interventions on renal function-Is there a benefit to staging?

Shah M, Gajanana D, Wheeler DS, Punjabi C, Maludum O, Mezue K, Lerma EV, Ardati A, Romero-Corral A, Witzke C, Rangaswami J.

Cardiovasc Revasc Med. 2017 Jul - Aug;18(5):344-348. doi: 10.1016/j.carrev.2017.02.017. Epub 2017 Feb 28.

PMID:
28285786
7.

Image noise reduction technology reduces radiation in a radial-first cardiac catheterization laboratory.

Gunja A, Pandey Y, Xie H, Wolska BM, Shroff AR, Ardati AK, Vidovich MI.

Cardiovasc Revasc Med. 2017 Apr - May;18(3):197-201. doi: 10.1016/j.carrev.2016.12.017. Epub 2016 Dec 27.

PMID:
28089778
8.

Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome.

Kim K, Lee TA, Touchette DR, DiDomenico RJ, Ardati AK, Walton SM.

J Manag Care Spec Pharm. 2017 Jan;23(1):57-63. doi: 10.18553/jmcp.2017.23.1.57.

9.

Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes.

Ismail S, Lee YM, Patel M, Duarte JD, Ardati AK.

Expert Rev Cardiovasc Ther. 2014 Nov;12(11):1289-303. doi: 10.1586/14779072.2014.970180. Review.

PMID:
25340283
10.

Current medical management of stable coronary artery disease before and after elective percutaneous coronary intervention.

Ardati AK, Pitt B, Smith DE, Aronow HD, Share D, Moscucci M, Chetcuti S, Grossman PM, Gurm HS.

Am Heart J. 2013 May;165(5):778-84. doi: 10.1016/j.ahj.2013.01.015. Epub 2013 Feb 19.

PMID:
23622915
11.

The quality and impact of risk factor control in patients with stable claudication presenting for peripheral vascular interventions.

Ardati AK, Kaufman SR, Aronow HD, Nypaver TJ, Bove PG, Gurm HS, Grossman PM.

Circ Cardiovasc Interv. 2012 Dec;5(6):850-5. doi: 10.1161/CIRCINTERVENTIONS.112.975862. Epub 2012 Dec 11.

PMID:
23233746
12.

Understanding DP receptor antagonism using a CoMSIA approach.

Mu L, Aguiar J, Ardati A, Cao B, Gardner CJ, Gillespy T, Harris K, Lim S, Marcus R, Morize I, Parkar A, Stefany D, Li Y, Vaz RJ, Cirovic DA.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):66-75. doi: 10.1016/j.bmcl.2010.11.071. Epub 2010 Nov 21.

PMID:
21147533
13.

Prediction of the 3D structure and dynamics of human DP G-protein coupled receptor bound to an agonist and an antagonist.

Li Y, Zhu F, Vaidehi N, Goddard WA 3rd, Sheinerman F, Reiling S, Morize I, Mu L, Harris K, Ardati A, Laoui A.

J Am Chem Soc. 2007 Sep 5;129(35):10720-31. Epub 2007 Aug 11.

14.
15.

Statin-associated rhabdomyolysis.

Ardati A, Stolley P, Knapp DE, Wolfe SM, Lurie P.

Pharmacoepidemiol Drug Saf. 2005 Apr;14(4):287. No abstract available.

PMID:
15782398
16.

Fluid shear stress differentially regulates gpr3, gpr6, and gpr12 expression in human umbilical vein endothelial cells.

Uhlenbrock K, Huber J, Ardati A, Busch AE, Kostenis E.

Cell Physiol Biochem. 2003;13(2):75-84.

PMID:
12649592
17.

Sphingosine 1-phosphate and dioleoylphosphatidic acid are low affinity agonists for the orphan receptor GPR63.

Niedernberg A, Tunaru S, Blaukat A, Ardati A, Kostenis E.

Cell Signal. 2003 Apr;15(4):435-46.

PMID:
12618218
18.

Induction of heat shock protein 70 by herbimycin A and cyclopentenone prostaglandins in smooth muscle cells.

Hamel L, Kenney M, Jayyosi Z, Ardati A, Clark K, Spada A, Zilberstein A, Perrone M, Kaplow J, Merkel L, Rojas C.

Cell Stress Chaperones. 2000 Apr;5(2):121-31.

19.

Human CRF2 alpha and beta splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay.

Ardati A, Goetschy V, Gottowick J, Henriot S, Valdenaire O, Deuschle U, Kilpatrick GJ.

Neuropharmacology. 1999 Mar;38(3):441-8.

PMID:
10219982
20.

Pharmacological characterisation of the recombinant human CRF binding protein using a simple assay.

Ardati A, Gottowik J, Henriot S, Clerc RG, Kilpatrick GJ.

J Neurosci Methods. 1998 Mar 13;80(1):99-105.

PMID:
9606055
21.

A new family of orphan G protein-coupled receptors predominantly expressed in the brain.

Valdenaire O, Giller T, Breu V, Ardati A, Schweizer A, Richards JG.

FEBS Lett. 1998 Mar 13;424(3):193-6.

22.

Interaction of [3H]orphanin FQ and 125I-Tyr14-orphanin FQ with the orphanin FQ receptor: kinetics and modulation by cations and guanine nucleotides.

Ardati A, Henningsen RA, Higelin J, Reinscheid RK, Civelli O, Monsma FJ Jr.

Mol Pharmacol. 1997 May;51(5):816-24.

PMID:
9145920
23.

Orphan receptors and their natural ligands.

Civelli O, Nothacker HP, Bourson A, Ardati A, Monsma F, Reinscheid R.

J Recept Signal Transduct Res. 1997 Jan-May;17(1-3):545-50. Review. No abstract available.

PMID:
9029514
24.

Moving from the orphanin FQ receptor to an opioid receptor using four point mutations.

Meng F, Taylor LP, Hoversten MT, Ueda Y, Ardati A, Reinscheid RK, Monsma FJ, Watson SJ, Civelli O, Akil H.

J Biol Chem. 1996 Dec 13;271(50):32016-20.

25.

The atrial natriuretic factor promoter is a downstream target for Nkx-2.5 in the myocardium.

Durocher D, Chen CY, Ardati A, Schwartz RJ, Nemer M.

Mol Cell Biol. 1996 Sep;16(9):4648-55.

26.

Primary structure and tissue distribution of the orphanin FQ precursor.

Nothacker HP, Reinscheid RK, Mansour A, Henningsen RA, Ardati A, Monsma FJ Jr, Watson SJ, Civelli O.

Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8677-82.

27.

Structure-activity relationship studies on the novel neuropeptide orphanin FQ.

Reinscheid RK, Ardati A, Monsma FJ Jr, Civelli O.

J Biol Chem. 1996 Jun 14;271(24):14163-8.

28.

Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor.

Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ Jr, Civelli O.

Science. 1995 Nov 3;270(5237):792-4.

PMID:
7481766
29.

Developmental stage-specific regulation of atrial natriuretic factor gene transcription in cardiac cells.

Argentin S, Ardati A, Tremblay S, Lihrmann I, Robitaille L, Drouin J, Nemer M.

Mol Cell Biol. 1994 Jan;14(1):777-90.

30.

Supplemental Content

Loading ...
Support Center